Vir Biotechnology, Inc. (VIR) Debt to Equity Ratio
Vir Biotechnology, Inc. (VIR) debt-to-equity ratio history and balance sheet leverage. Analyze D/E ratio in Excel with MarketXLS.
Debt to Equity Ratio Data
| Period | Debt/Equity |
|---|---|
| 2020-12-31 | 0.09 |
| 2021-12-31 | 0.09 |
| 2022-12-31 | 0.06 |
| 2023-12-31 | 0.07 |
| 2024-12-31 | 0.09 |
| 2025-12-31 | 0.12 |
Debt to equity divides total borrowings by total shareholder equity at the period end. Total borrowings are short-term debt plus long-term debt, including capital lease obligations. Non-debt liabilities such as accounts payable and deferred revenue are excluded. A period is omitted when equity is negative, because the ratio is not meaningful then.
How VIR compares with sector peers
| Symbol | Company | Debt/Equity (latest fiscal year) |
|---|---|---|
| ABEO | Abeona Therapeutics Inc. | 0.15 |
| RIGL | Rigel Pharmaceuticals Inc. | 0.13 |
| REGN | Regeneron Pharmaceuticals Inc. | 0.09 |
| EW | Edwards Lifesciences Corporation | 0.07 |
| IOVA | Iovance Biotherapeutics Inc. | 0.06 |
These are five companies in the same sector as VIR with a comparable annual debt to equity ratio. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Vir Biotechnology, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Debt_to_Equity_Ratio("VIR", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | VIR | $9.78 | +6.19% | 1.76M |
| 3 | ||||
| 4 | ||||
| 5 |